The impacts of biologic treatment on metabolic profiling in psoriasis
Authors:
- 17 January 2024
- journal article
- research article
- Published by Wiley in Experimental Dermatology
- Vol. 33 (1) , e15011
Abstract
Psoriasis is an immune‐mediated inflammatory disease commonly accompanied by various metabolic disorders. It is widely known that biologics could affect the metabolic status and comorbidities in psoriasis patients, however, the effects of biologics on metabolism in psoriasis patients remain poorly understood. The aim of this study was to elucidate the characteristic changes of metabolic profiling in psoriasis vulgaris (PsV) patients before and after applying biologics. Plasma samples were collected from a retrospective cohort of 43 PsV patients. Non‐targeted metabolomics analyses were performed using liquid chromatography‐mass spectrometry (LC–MS) to compare the metabolic profiles before and after applying adalimumab (ADA) or ixekizumab (IXE) for 4 weeks. Additionally, correlation analyses were conducted to investigate the associations between metabolite expression levels and clinical characteristics. The biologics significantly affected the metabolic profiles of PsV patients especially in glycerophospholipids (GPs). First, phosphatidylcholine (PC), unsaturated lysophosphatidylcholine (LPC), unsaturated lysophosphatidic acid (LPA) and unsaturated lysophosphatidylethanolamine (LPE) were significantly up‐regulated, whereas phosphatidylethanolamine (PE), saturated LPC, saturated LPA and saturated LPE were predominantly down‐regulated after biologic treatment. What is more, the changes in PE and LPA were mainly observed after applying IXE instead of ADA. Second, we also found GPs including PC, unsaturated LPC, unsaturated LPA and unsaturated LPE were primarily negatively correlated with disease severity, whereas, PE, saturated LPC, saturated LPA and saturated LPE displayed inverse correlations. Biologics could affect GP metabolism and facilitate the transition of metabolic status from a pro‐inflammatory to an anti‐inflammatory phenotype in PsV patients.Keywords
Funding Information
- National Natural Science Foundation of China (82373484, 82073447, 82003354, 82221002, 82130090)
- Fundamental Research Funds for Central Universities of the Central South University (2022ZZTS0861)
This publication has 46 references indexed in Scilit:
- The role of phosphatidylcholine and choline metabolites to cell proliferation and survivalCritical Reviews in Biochemistry and Molecular Biology, 2013
- Protective Effect of Phosphatidylcholine on Lipopolysaccharide-Induced Acute Inflammation in Multiple Organ InjuryThe Korean Journal of Physiology & Pharmacology, 2013
- Prevention of 1-palmitoyl lysophosphatidylcholine-induced inflammation by polyunsaturated acyl lysophosphatidylcholineInflammation Research, 2012
- Single Lysophosphatidylcholine Components Exhibit Adjuvant Activities In Vitro and In VivoClinical and Vaccine Immunology, 2010
- Anti-inflammatory effects of phosphatidylcholine in neutrophil leukocyte-dependent acute arthritis in ratsEuropean Journal of Pharmacology, 2009
- Oral phosphatidylcholine pretreatment alleviates the signs of experimental rheumatoid arthritisArthritis Research & Therapy, 2009
- Impaired TCR signaling through dysfunction of lipid rafts in sphingomyelin synthase 1 (SMS1)-knockdown T cellsInternational Immunology, 2008
- Sphingomyelin Synthase 2 Deficiency Attenuates NFκB ActivationArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Psoriasis and metabolic disease: epidemiology and pathophysiologyCurrent Opinion in Rheumatology, 2008
- Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokinesJournal of Molecular and Cellular Cardiology, 2003